Antibody-directed enzyme prodrug therapy (ADEPT)

Drugs of the Future

Volumn 21, Issue 2, 1996, Pages 167-181

  Melton, Roger G ^a   Knox, Richard J ^b   Connors, Tom A ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA GALACTOSIDASE; AMINOPEPTIDASE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; AZO REDUCTASE; BETA GLUCURONIDASE; BETA LACTAMASE; CARBOXYPEPTIDASE G2; CHLORMETHINE; DAUNORUBICIN; DOXORUBICIN; ENZYME ANTIBODY COMPLEX; ETOPOSIDE; FLUOROURACIL; GANCICLOVIR TRIPHOSPHATE; GLUCOSE OXIDASE; HYDROGEN PEROXIDE; MELPHALAN; METHOTREXATE; MITOMYCIN; NITROREDUCTASE; PALYTOXIN; PENICILLIN AMIDASE; PLASMIN; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIDARABINE TRIPHOSPHATE; XANTHINE OXIDASE;

CHEMOTHERAPY; CONJUGATE; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW;

EID: 0030002918     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Knox, R.J., Friedlos, F., Boland, M.P. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 1993, 12: 195-212.
2. Connors, T.A., Whisson, M.E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: The relationship between glucuronidase activity and tumour sensitivity. Nature 1966, 210: 866-7.
3. Young, C.W., Yagoda, A., Bittar, E.S., Smith, S W., Grabstald, H., Whitmore, W. Therapeutic trial of aniline mustard in patients with advanced cancer. Comparison of therapeutic response with cytochemical assessment of tumor cell beta-glucuronidase activity. Cancer 1976. 38: 1887-95.
4. Ehrlich, P. (Ed.). The Collected Papers of P. Ehrlich Pergamon Press: London 1960.
5. Pimm, M.V. Drug-monoclonal antibody conjugates for cancer therapy: Potential and limitations. CRC Crit Rev Ther Drug Carrier Syst 1988, 5: 189-227.
6. Wawrzynczak, E J. Systemic immunotoxin therapy of cancer: Advances and prospects. Brit J Cancer 1991, 64: 624-30.
7. Shockley, T.R., Lin, K., Nagy, J.A., Tompkins, R.G., Yarmush, M.L., Dvorak, H.F. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 1992, 52: 367-76
8. Bagshawe, K.D. Antibody directed enzymes revive anti-cancer prodrugs concept. Brit J Cancer 1987, 56: 531-2.
9. Bagshawe, K.D., Springer, C.J., Searle, F. et al. A cytotoxic agent can be generated selectively at cancer sites. Brit J Cancer 1988, 58: 700-3.
10. Bagshawe, K.D. Antibody-directed enzyme prodrug therapy (ADEPT). Adv Pharmacol 1993, 24: 99-121.
11. Stanislawski, M., Rousseau, V., Goavec, M., Ito, H. Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: In vitro killing effectiveness in a mouse plasmacytoma cell model. Cancer Res 1989, 49: 5497-504.
12. Muzykantov, V.R., Trubetskaya, O.V., Puchnina, E.A., Sakharov, D.V., Domogatsky, S.P. Cytotoxicity of glucose oxidase conjugated with antibodies to target cells: Killing efficiency depends on conjugate internalization. Biochim Biophys Acta 1990, 1053: 27-31
13. Muzykantov, V.R., Saharov, D.V., Sinitsyn, V.V., Domogatsky, S.P., Goncharov, N.V., Danilov, S.M. Specific killing of human endothelial cells by antibody-conjugated glucose oxidase. Anal Chem 1988, 169: 383-9.
14. Ito, H., Morizet, J., Coulombel, L. et al. An immunotoxin system intended for bone marrow purging composed of glucose oxidase and lactoperoxidase coupled to monoclonal antibody 097. Bone Marrow Transplant 1989, 4. 519-27.
15. Ito, H Morizet, J., Coulombel, L., Stanislawski, M. T cell depletion of human bone marrow using an oxidase-peroxidase enzyme immunotoxin. Bone Marrow Transplant 1990, 6: 395-8.
16. Frei, E., Teicher, B.A., Holden, S.A., Cathcart, K.N.S., Wang, Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988, 48: 6417-23.
17. Culver, K W., Ram, Z., Wallbridge, S, Ishii, H., Oldfield, E.H., Blaese, R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256, 1550-2
18. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M., Oldfield, E.H In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993, 53: 83-8.
19. Culver, K.W., Van Gilder, J., Link, C.J. et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 1994, 5: 343-79.
20. Huber, B.E., Richards, C.A., Austin, E.A. Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann NY Acad Sci 1994, 716: 104-14.
21. Mullen, C.A., Kilstrup, M., Blaese, R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA 1992, 89: 33-7.
22. Mullen, C.A., Coale, M M., Lowe, R., Blaese, R.M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994, 54: 1503-6.
23. Huber, B.E., Austin, E.A., Richards, C.A., Davis, S.T., Good, S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994, 91: 8302-6.
24. Vile, R.G., Hart, I.R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993, 53: 3860-4.
25. Barba, D., Hardin, J., Ray, J., Gage, F.H. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993, 79: 729-35.
26. Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G., Woo, S.L. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994, 91. 3054-7.
27. Bridgewater, J., Springer, C.J., Knox, R.J., Minton, N.P., Michael, N.P., Collins, M. Expression of bacterial nitroreductase in mammalian cells renders them selectively sensitive to killing by CB 1954. Eur J Cancer 1995, 31A: 2362-70.
28. Connors, T.A The choice of prodrugs for GDEPT (gene-directed enzyme prodrug therapy) of cancer. Gene Ther 1995, 2: 702-9.
29. Minton, N.P., Atkinson, T., Bruton, C.J., Sherwood, R.F. The complete nucleotide sequence of the Pseudomomas gene coding for carboxypeptidase G2. Gene 1984, 31: 31-8.
30. Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, F., Bisset, G.M.F., Jarman, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2 J Med Chem 1990, 33: 677-81.
31. Bagshawe, K.D., Sharma, S.K., Spinger, C.J. et al. Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconj Radiopharm 1991, 4: 915-22.
32. Bagshawe, K.D., Sharma, S.K, Springer, C.J. et al. Antibody directed enzyme prodrug therapy (ADEPT): Clinical report. Dis Markers 1991, 9: 233-8.
33. Springer, C.J., Antoniw, P., Bagshawe, K.D., Wilman, D.E. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des 1991, 6: 467-79.
34. Springer, C.J., Bagshawe, K.D, Sharma, S.K. et al. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 1991, 27: 1361-6.
35. Bagshawe, K D. Towards generating cytotoxic agents at cancer sites. Brit J Cancer 1989, 60: 275-81.
36. Ecoles, S.A., Court, W.J., Box, G.A., Dean, C.J., Melton, R.G., Springer, C.J. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 1994, 54: 5171-7.
37. Blakey, D.C., Valcaccia, B.E, East, S. et al. Antitumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys 1993, 22: 1-8.
38. Philben, V.J., Jakowatz, J.G., Beatty, B.G. et al. The effect of tumour CEA content and tumour size on uptake of indium 111 labelled anti-CEA antibody. Cancer 1986, 57: 571-6.
39. Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, R.W, Rogers, G.T. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Brit J Cancer 1990, 61: 659-62.
40. Sharma, S.K., Bagshawe, K.D., Springer, C.J. et al. Antibody directed enzyme prodrug therapy (ADEPT): A three phase system. Dis Markers 1991, 9: 225-31.
41. Sharma, S.K., Bagshawe, K.D., Melton, R.G., Sherwood, R.F. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992, 21: 109-20.
42. Springer, C.J., Poon, G.K., Sharma, S.K., Bagshawe, K.D. Identification of prodrug, active drug and metabolites in an ADEPT clinical study. Cell Biophys 1993, 22: 9-26.
43. Dowell, R.I., Boyle, F.T., Davies, D.H. et al. New mustard prodrugs for ADEPT: An in vitro profile. Brit J Cancer 1994, 69 (Suppl. 21): 41.
44. Kuefner, U., Lohrmann, U., Montejano, Y.D., Vitols, K.S., Huennekens, F.M. Carboxypeptidase-mediated release of methotrexate from methotrexate-α-peptides. Biochemistry 1989, 28: 2288-97.
45. Esswein, A., Hanseler, E., Montejano, Y., Vitols, K.S., Huennekens, F.M. Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate. Adv Enzyme Regul 1991, 31: 3-12.
46. Haenseler, E., Esswein, A., Vitols, K.S. et al. Activation of methotrexate-α-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry 1992, 31: 891-7.
47. Perron, M., Pagé, M. Synthesis of methotrexate prodrugs as an approach for drug targeting. Int J Oncol 1994, 5: 907-13.
48. Vitols, K.S., Haag-Zeino, B., Baer, T., Montejano, Y.D., Huennekens, F.M. Methotrexate-α-phenylalanine: Optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. Cancer Res 1995, 55: 478-81.
49. Smal, M.A., Dong, Z., Cheung, A. et al Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate Biochem Pharmacol 1995, 49: 567-74.
50. Senter, P.D., Saulnier, M.G., Schreiber, G.J. et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988, 85: 4842-6.
51. Senter, P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A , Hellstrom, K.E., Hellstom, I. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989, 49: 5789-92.
52. Senter, P.D. Activation of prodrugs by antibody-enzyme conjugates, a new approach to cancer therapy. FASEB J 1990, 4: 188-93.
53. Wallace, P.M., Senter, P.D. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjug Chem 1991, 2: 349-52.
54. Sahin, U., Hartmann, F., Senter, P. et al. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 1990, 50: 6944-8.
55. Haisma, H.J., Boven, E. van Muijen, M., Devries, R., Pinedo, H.M. Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol Immunother 1992, 34: 343-8.
56. Roffler, S.R., Wang, S M., Chern, J.W., Yen, M.Y., Tung, E. Antineoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 1991, 42: 2062-5.
57. Wang, S.M., Chern, J W., Yeh, M.Y , Ng, Y C., Tung, E., Roffler, S.R. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 1992, 52: 4484-91.
58. Haisma, H.J., Boven, E., van Muijen, M, Dejong, J., Vandervijgh, W.J.F., Pinedo, H.M. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Brit J Cancer 1992, 66: 474-8.
59. Andrianomenjanahary, S., Dong, X, Florent, J.C. et al. Synthesis of novel targeted pro-prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate. Bioorg Med Chem Lett 1992, 2: 1093-6.
60. Rowlinson-Busza, G., Bamias, A., Krausz, T. et al Antibody-guided enzyme nitrile therapy (AGENT): In vitro cytotoxicity and in vivo tumour localisation. In. Monoclonal Antibodies. Applications in Clinical Oncology. Epenetos, A.A. (Ed). Chapman Hall: London 1992, 111-8.
61. Alexander, R.P, Beeley, N.R.A., O'Driscoll, M., O'Neill, F.P., Millican, T.A. Cephalosporin nitrogen mustard carbamate prodrugs for "ADEPT". Tetrahedron Lett 1991, 32: 3269-72.
62. Svensson, H.P., Kadow, J.F., Vrudhula, V.M , Wallace, P.M., Senter, P.D. Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug Chem 1992, 3: 176-81.
63. Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Wallace, P.M., Senter, P.D. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconjug Chem 1993, 4: 334-40.
64. Shepherd, T.A., Jungheim, L.N., Meyer, D.M et al. A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Bioorg Med Chem Lett 1991, 1: 21-6.
65. Meyer, D.L., Jungheim, L.N., Mikolajczyk, S.D. et al. Preparation and characterization of a β-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents. Bioconjug Chem 1992, 3, 42-8.
66. Meyer, D.L., Jungheim, L.N., Law, K.L. et al. Site-specific prodrug activation by antibody-beta-lactamase conjugates: Regression and long-term growth inhibition of human colon carcinoma xenograft models Cancer Res 1993, 53: 395-63
67. Kerr, D.E., Senter, P.D., Burnett, W.V. et al. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother 1990, 31: 202-6.
68. Vrudhula, V.M., Senter, P.D., Fischer, K.J. et al. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J Med Chem 1993. 36: 919-23.
69. Bignami, G.S., Senter, P.D., Grothaus, P.G. et al. N-(4′-hydroxyphenylacetyl)palytoxin, a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res 1992, 52: 5759-64.
70. Senter, P.D., Su, P.C.D., Katsuragi, T. et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 1991, 2: 447-51.
71. Wallace, P.M., MacMaster, J.F., Smith, V.F., Kerr, D.E., Senter, P.D., Cosand, W.L Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 1994, 54: 2719-23.
72. Anlezark, G.M., Melton, R G., Sherwood, R.F., Coles, B., Friedlos, F., Knox, R.J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) I Purification and properties of a nitroreductase enzyme from Escherichia coli - A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992, 44: 2289-95.
73. Knox, R.J., Friedlos, F., Sherwood, R.F., Melton, R.G., Anlezark, G.M. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992. 44. 2297-301.
74. Mauger, A.B., Burke, P.J., Somani, H.F., Friedlos, F., Knox, R.J. Self-immolative prodrugs: Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem 1994, 37: 3452-8.
75. Friedlos, F., Knox, R.J Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochem Pharmacol 1992, 44: 631-5.
76. Knox, R.J , Friedlos, F., Jarman, M. et al. Virtual cofactors for an E. coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1995, 49: 1641-7.
77. Sharma, S.K., Bagshawe, K.D., Burke, P.J. et al. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 1994, 73: 1114-20.
78. Melton, R.G., Rowland, J.A., Pietersz, G.A., Sherwood, R.F., McKenzie, I.F.C. Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate. Eur J Cancer 1993, 8: 1177-83.
79. Sehon, A.H. Suppression of antibody responses by chemically modified antigens. Int Arch Allergy Appl Immunol 1991, 94: 11-20.
80. De-Sutter, K., Fiers, W. A bifunctional murine: Human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase. Mol Immunol 1994, 31: 261-7
81. Goshorn, S.C., Svensson, H.P., Kerr, D.E., Somerville, J.E., Senter, P.D., Fell, H.P. Genetic construction, expression, and characterization of a single chain anticarcinoma antibody fused to beta-lactamase. Cancer Res 1993, 53: 2123-7.
82. Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Schuermann, M., Seemann, G. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Brit J Cancer 1992, 65: 234-8.
83. Bosslet, K., Czech, J., Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994, 54: 2151-9.
84. Partridge, L.J. Production of catalytic antibodies using combinatorial libraries. Biochem Soc Trans 1993, 21: 1096-8.
85. Chester, K.A., Begent, R.H., Robson, L. et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994, 343: 455-6.
86. Campbell, D.A., Gong, B., Kochersperger, L.M., Yonkovich, S., Gallop, M.A., Schultz, P.G. Antibody-catalyzed prodrug activation. J Amer Chem Soc 1994, 116: 2165-6.
87. Chakravarty, P.K., Carl, P.L., Weber, M.J., Katzenellenbogen, J.A. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J Med Chem 1983, 26: 638-44.
88. 1 and susceptibilities to gamma-glutamyl para-phenylene diamine mustard of gamma-glutamyl transferase negative and positive cell lines. Carcinogenesis 1981, 2: 661-70.
89. Bukhari, A., Connors, T.A., Gilsenan, A.M. et al. Cytotoxic agents designed to be selective for liver cancer. J Natl Cancer Inst 1973, 50: 243-7.